Msp2 variation inAnaplasma phagocytophilum in vivodoes not stimulate T cell immune responses or interferon-γ production

This publication has 44 references indexed in Scilit:

• Innate Immune Response toAnaplasma phagocytophilumContributes to Hepatic Injury
  Clinical and Vaccine Immunology, 2006
• Rapid Sequential Changeover of Expressed p44 Genes during the Acute Phase of Anaplasma phagocytophilum Infection in Horses
  Infection and Immunity, 2004
• Comparison of patients fulfilling criteria for confirmed and probable human granulocytic ehrlichiosis
  Scandinavian Journal of Infectious Diseases, 2004
• Frontline: Control of Anaplasma phagocytophilum, an obligate intracellular pathogen, in the absence of inducible nitric oxide synthase, phagocyte NADPH oxidase, tumor necrosis factor, Toll‐like receptor (TLR)2 and TLR4, or the TLR adaptor molecule MyD88
  European Journal of Immunology, 2004
• CD4 ⁺ T Lymphocytes from Anaplasma marginale Major Surface Protein 2 (MSP2) Vaccinees Recognize Naturally Processed Epitopes Conserved in MSP3
  Infection and Immunity, 2004
• Major Surface Protein 2 of Anaplasma phagocytophilum Facilitates Adherence to Granulocytes
  Infection and Immunity, 2003
• Genetic Variability and Stability of Anaplasma phagocytophila msp2 ( p44 )
  Infection and Immunity, 2002
• Pathology, Immunohistology, and Cytokine Responses in Early Phases of Human Granulocytic Ehrlichiosis in a Murine Model
  The Journal of Infectious Diseases, 2000
• Development and Distribution of Pathologic Lesions Are Related to Immune Status and Tissue Deposition of Human Granulocytic Ehrlichiosis Agent–Infected Cells in a Murine Model System
  The Journal of Infectious Diseases, 1999
• Immunization against the agent of human granulocytic ehrlichiosis in a murine model.
  Journal of Clinical Investigation, 1997